Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$6.55 USD
-0.44 (-6.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.60 +0.05 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.55 USD
-0.44 (-6.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.60 +0.05 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
by Zacks Equity Research
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
by Zacks Equity Research
Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions have been highlighted in this Investment Ideas article.
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
by Andrew Rocco
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
Repligen (RGEN) Q2 Earnings Meet Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
by Zacks Equity Research
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
by Zacks Equity Research
Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
by Zacks Equity Research
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) are on a downward trajectory since the ticker was dropped from the S&P SmallCap 600 index.
Apellis (APLS) Updates on Safety Concerns for Syfovre
by Zacks Equity Research
Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
by Zacks Equity Research
Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
by Zacks Equity Research
Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
by Zacks Equity Research
Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
by Zacks Equity Research
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?